MENU

TRAW Stock Traws Pharma (TRAW, $1.4) Stochastic Oscillator left the oversold zone on August 29, 2025

A.I.dvisor
at Tickeron.com
Loading...
TRAW - Traws Pharma Inc
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $1.4
Daily change: -$0.02 (-1.41%)
Daily volume: 45.8K
Capitalization: $9.9M
Industry: Biotechnology
This is a signal that TRAW's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 70 similar cases where TRAW's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

TRAW sees MACD Histogram just turned negative

TRAW saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 18, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TRAW as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

TRAW moved below its 50-day moving average on August 15, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TRAW crossed bearishly below the 50-day moving average on August 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRAW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TRAW's RSI Oscillator exited the oversold zone, of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 70 cases where TRAW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRAW advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

TRAW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 82 cases where TRAW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.197) is normal, around the industry mean (19.823). P/E Ratio (0.334) is within average values for comparable stocks, (52.034). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.525). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (2.361) is also within normal values, averaging (321.242).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TRAW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRAW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a company which engages in the identification and development of oncology therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12 Penns Trail
Phone
+1 267 759-3680
Employees
17
Web
https://www.onconova.com